Huntingdon Life Sciences and Harlan Laboratories to Become Envigo
Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the combined companies will be called Envigo.
When the new name and brand is launched later this year it will be a significant milestone for the combined organization, marking great progress in integrating the companies and building on a heritage of more than 80 years.
The name Envigo is made from a combination of words that reflect the identity of the new company. The letters “E and N” come from “enhance, enrich and enable,” … the company helps make the world a better place through advancing the research and product development of its customers. “VIGO” originates in “vigorous and invigorate”, and the Latin word “vita” meaning “life”… so being dynamic and strong, imparting vitality, energy and life.
Brian Cass, CEO, commented: “This is a hugely exciting time for our company. We at Envigo will be united with our customers in the knowledge that the research they conduct, and the products we help them develop, have the potential to enhance life. Our new name and brand will reflect our integrated management structure and the broader product and service offerings of our combined organization.”
Adrian Hardy, COO, added: “Our customers are looking for partners who understand their goals, take ownership of projects, and deliver high quality products and science. Our goal is to establish Envigo as the number one partner for both customer service and scientific expertise.”
The combined organization has 3800 people and sales approaching $500 million. As a result of the integration, the company is the largest provider of research services to the crop protection and chemical industries, the second largest supplier of research models and services, and the third largest in the preclinical pharmaceutical development arena.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance